companiesCompany
Acrotech Biopharma
Acrotech Biopharma, part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate (Folotyn), belinostat (Beleodaq) and vincristine liposome (Marqibo).
Overview
Acrotech acquired Spectrum's marketed products in 2019, including Zevalin (ibritumomab tiuxetan) for follicular lymphoma, Folotyn and Beleodaq for peripheral T-cell lymphoma, Marqibo and Evomela (melphalan).
Headquarters
East Windsor, New Jersey, US
Scorecard
All companies#85of 680 companies, score 31
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +19
1 approved, 0 in phase 3, 0 earlier, 1 targets, 88 registry studies. Formula on the scorecards page.
Type
pharma
Website